Observation vs. Targeted High-Dose Radiation for Metastatic Prostate Cancer

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, MARCH 26, 2020

Media advisory: The full study and commentary are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2020.0147?guestAccessKey=e5501192-c562-4e38-9167-81da44e28982&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=032620

 

What The Study Did: This randomized clinical trial compared how effectively high-dose, targeted radiation therapy versus no treatment (observation) among 54 men prevented the progression over six months of recurrent hormone-sensitive prostate cancer that has metastasized to a small number of sites in the body.

Authors: Phuoc T. Tran, M.D., Ph.D., of the Johns Hopkins University School of Medicine in Baltimore, is the corresponding author.

 

(doi:10.1001/jamaoncol.2020.0147)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the articles for additional information, including other authors, author contributions and affiliations, conflicts of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.